Maxim's Ceplene Fails Trial In Advanced Malignant Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will continue to pursue approval for acute myeloid leukemia indication. Maxim plans to review its pipeline, operations and resources to focus on advancing Ceplene and other products to market.